Publications by authors named "Lilly C Lee"
Article Synopsis
- * A case-control study involving 3,647 healthcare personnel showed that bivalent vaccine effectiveness (VE) was about 34.1%, with the highest effectiveness (54.8%) observed shortly after administration, declining as time passed.
- * The study highlights that while bivalent doses initially provide substantial protection against COVID-19, their effectiveness significantly wanes after two months, suggesting the need for ongoing monitoring and potential updates to vaccination strategies.
Article Synopsis
- Protection against COVID-19 is crucial for healthcare workers, especially as vaccine effectiveness has decreased with the rise of the Omicron variant.
- A study evaluated the effectiveness of a monovalent mRNA booster dose from October 2021 to June 2022, finding that its effectiveness dropped significantly from 86% during Delta prevalence to 65% during Omicron prevalence.
- The results indicated that while a booster dose provides strong protection initially, its effectiveness wanes over time, dropping to 32% at least 120 days after vaccination, highlighting the importance of staying current with COVID-19 vaccinations.
Article Synopsis
- The study examined the effectiveness of mRNA vaccines (Pfizer-BioNTech and Moderna) against COVID-19 among U.S. health care personnel who were prioritized for early vaccination.
- It utilized a test-negative case-control design, comparing vaccinated individuals with positive SARS-CoV-2 tests (cases) to those with negative tests (controls) while adjusting for various demographics and health factors.
- Results showed that partial vaccination had effectiveness rates of 77.6% for Pfizer and 88.9% for Moderna, while complete vaccination led to 88.8% and 96.3% effectiveness, respectively, with some variations noted in specific demographic subgroups and over time.
Article Synopsis
- Health care personnel (HCP) were prioritized for COVID-19 vaccination to protect them from SARS-CoV-2 exposure and ensure ongoing health services during the pandemic.
- Early distributions of Pfizer-BioNTech and Moderna vaccines allowed for real-world effectiveness assessments among HCP at 33 U.S. sites.
- Interim analyses showed a vaccine effectiveness of 82% after one dose and 94% after two doses, confirming their strong protection against symptomatic illness comparable to clinical trial results.